Blocking CTLA-4 and PD-1 can improve the prognosis of some cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma (Brahmer et al., 2012; Topalian et al., 2012). The gene discussed is PDCD1; the disease is melanoma.